BBD-1 immune therapy for IgA vasculitis
Part of Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called BBD-1 that may help treat IgA vasculitis, a condition where your immune system attacks small blood vessels, causing a purple rash and organ damage. The study measures how well BBD-1 reduces symptoms and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Doctor has confirmed you have IgA vasculitis (a blood vessel inflammation with IgA protein deposits)
- You have a purple rash (purpura) and/or damage to at least one organ (kidneys, joints, or intestines)
- You are not currently enrolled in another medical study with an experimental treatment
- You have signed and understand the informed consent form
- You have active social security insurance or equivalent health coverage
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BDB-001 for people with a type of blood vessel inflammation (ANCA vasculitis, specifically GPA or MPA). It aims to see if adding BDB-001 to standard treatment can help control the disease better.
This trial tests a new medicine called BHV-1400 for adults with IgA nephropathy, a kidney disease that can cause protein in the urine and kidney damage. The goal is to see if it's safe and effective in slowing the disease.
This study tests a new drug called CM336 for people with autoimmune blistering diseases. The drug is designed to calm the immune system and reduce blistering, aiming to improve skin health.
This trial tests a new medicine called RAY121 (an antibody) for people with certain autoimmune diseases. It aims to see if RAY121 is safe and how the body handles it. If you have one of these conditions and meet the basic health requirements, you might be able to join.
This trial tests a new treatment called BCT301 for people with IgG4-related disease (an autoimmune condition causing swelling in organs like the pancreas or kidneys) that has not improved with standard treatments. The therapy targets certain immune cells to help reduce disease activity.
This trial tests a personalized approach that uses a blood test to help guide targeted therapies for IgA nephropathy and IgA vasculitis. It may help reduce kidney damage and control the disease with fewer side effects.
Hear when a new Allergic Reaction (IgA) Vasculitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.